About Diakonos
Diakonos is a company based in Houston (United States) founded in 2022. Diakonos has raised $31.4 million across 2 funding rounds from investors including Baylor College of Medicine, Restem and Brain Tumor Investment Fund. Diakonos offers products and services including DOC1021. Diakonos operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Houston, United States
- SectorsHealthcare
- Website diakonosoncology.com
- Social LinkedIn
- Legal Name Diakonos Oncology Corp.
- Total Equity Funding$31.4M (USD)
in 2 rounds
- Latest Funding Round$20M (USD), Seed
Jun 2025
- InvestorsBaylor College of Medicine
& 2 more
Products & Services of Diakonos
Diakonos offers a comprehensive portfolio of products and services, including DOC1021.
Vaccine that stimulates immune response against cancer by mimicking viral infections.
Funding Insights of Diakonos
Diakonos has successfully raised a total of $31.4M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $20 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $31.4M
- Total Rounds 2
- Last Round Seed — $20M
- First Round $11.4M
(Aug 2024)
- Investors Count 3
All 2 funding rounds of Diakonos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $20M | Seed | – | – | |
| Aug 2024 | $11.4M | Seed | – | Restem | – |
3 investors in total: 3 institutional.
Investors in Diakonos
Diakonos has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Baylor College of Medicine, Restem and Brain Tumor Investment Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Philanthropic capital is invested to advance brain tumor treatments. | – | braintumorinvestmentfund.org | Newton, United States | |
Health science courses and degrees are offered to students. | 1900 | bcm.edu | United States | |
Advances cell therapies for autoimmune conditions through proprietary platforms. | 2016 | restem.com | Corona, United States |
Investor details for Diakonos
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Diakonos
1 people are tracked at Diakonos (1 in leadership).
| Name | Role | Group |
|---|---|---|
Mike Wicks | CEO | Leadership |
Complete people profiles for Diakonos
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Diakonos
3 dated milestones of Diakonos across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Diakonos is founded.
- Funding First funding round of $11.4M.
- Funding Latest funding round, Seed, of $20.0M.
Competitors of Diakonos
Diakonos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Diakonos
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Diakonos
The website of Diakonos (diakonosoncology.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▼ 15.6% vs previous month
Latest news on Diakonos
Complete news archive for Diakonos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Diakonos
10 companies that operate in the same segment as Diakonos (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Diakonos
Diakonos was founded in 2022 and raised its 1st funding round 2 years after it was founded.
Diakonos is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Mike Wicks is the current CEO of Diakonos.
Diakonos is a funded company, having raised a total of $31.4M across 2 funding rounds to date. The company's 1st funding round was a Seed of $11.4M, raised on Aug 2024.
Diakonos was founded in 2022 and is headquartered in Houston, United States. Operations focus on the oncology sector, where immunotherapeutics are developed for cancer treatment. Services include dendritic cell vaccines targeting glioblastoma, pancreatic cancer, and sarcoma; intratumoral injections for bone and head and neck cancers; and CAR T cell therapies for HER2-positive breast cancer and solid tumors.
Diakonos's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Diakonos offers DOC1021.
Diakonos has 3 investors. Key investors include Baylor College of Medicine, Restem, and Brain Tumor Investment Fund.
Diakonos operates through Diakonos Oncology Corp..